UB Paderborn / Katalog / Suche / in CDI

Telaprevir for Retreatment of HCV Infection

The New England journal of medicine, 2011-06, Vol.364 (25), p.2417-2428

2011

Link zum Volltext

Verfügbarkeit prüfen

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

The New England journal of medicine, 2011-06, Vol.364 (25), p.2405-2416

2011

Link zum Volltext

Verfügbarkeit prüfen

Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study

Journal of hepatology, 2015-05, Vol.62 (5), p.1056-1060

2015

Link zum Volltext

Verfügbarkeit prüfen

Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study

Liver international, 2009-03, Vol.29 (3), p.415-419

2009

Link zum Volltext

Verfügbarkeit prüfen

Use of albumin in the treatment of cirrhosis: introduction

Annals of hepatology, 2011, Vol.10 Suppl 1, p.S5-S5

Terg, Ruben

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

Journal of hepatology, 2014-12, Vol.61 (6), p.1220-1227

2014

Link zum Volltext

Verfügbarkeit prüfen

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.1618-1628.e2

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

Journal of hepatology, 2002-12, Vol.37 (6), p.717-722

2002

Link zum Volltext

Verfügbarkeit prüfen

Large-Volume Paracentesis: Which Plasma Expander?

Ascites, Hyponatremia and Hepatorenal Syndrome: Progress in Treatment, 2010, Vol.28, p.32-39

2010

Link zum Volltext

Verfügbarkeit prüfen

Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2011-06, Vol.140 (7), p.1990-1999

2011

Link zum Volltext

Verfügbarkeit prüfen

Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients: a randomized, prospective and controlled trial

Gastrointestinal endoscopy, 2000-02, Vol.51 (2), p.157-163

2000

Link zum Volltext

Verfügbarkeit prüfen

Spontaneous bacterial peritonitis and pharmacologic acid suppression in patients with cirrhosis

Hepatology (Baltimore, Md.), 2013-01, Vol.57 (1), p.411-413

2013

Link zum Volltext

Verfügbarkeit prüfen

Primary biliary cirrhosis and hepatocellular carcinoma

Autoimmunity reviews, 2002-08, Vol.1 (4), p.220-225

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled study

Alimentary pharmacology & therapeutics, 2010-04, Vol.31 (8), p.834-845

2010

Link zum Volltext

Verfügbarkeit prüfen

M1267 Increased Intestinal Permeability (IP) in Cirrhosis is Associated to the Severity of the Liver Disease and a Higher Mortality

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-367-S-367

2010

Link zum Volltext

Verfügbarkeit prüfen

Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study

Journal of hepatology, 2008-05, Vol.48 (5), p.774-779

2008

Link zum Volltext

Verfügbarkeit prüfen

Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study

Hepatology (Baltimore, Md.), 2003-02, Vol.37 (2), p.359-365

2003

Link zum Volltext

Verfügbarkeit prüfen

Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study

Journal of hepatology, 2000-10, Vol.33 (4), p.564-569

2000

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study

Acta gastroenterologica latinoamericana, 2008-03, Vol.38 (1), p.26-33

2008

Link zum Volltext

Verfügbarkeit prüfen

Splenic hypofunction in cirrhosis is not associated with increased risk for infections

European journal of gastroenterology & hepatology, 1996-03, Vol.8 (3), p.257-260

1996

Link zum Volltext

Verfügbarkeit prüfen

295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.A-798-A-798

2009

Link zum Volltext

Verfügbarkeit prüfen

831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.A-809-A-809

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Telaprevir for Retreatment of HCV Infection

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study

Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study

Use of albumin in the treatment of cirrhosis: introduction

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

Large-Volume Paracentesis: Which Plasma Expander?

Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C

Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients: a randomized, prospective and controlled trial

Spontaneous bacterial peritonitis and pharmacologic acid suppression in patients with cirrhosis

Primary biliary cirrhosis and hepatocellular carcinoma

Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled study

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program

Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235]

M1267 Increased Intestinal Permeability (IP) in Cirrhosis is Associated to the Severity of the Liver Disease and a Higher Mortality

Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study

Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study

Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study

Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC 3 program

Splenic hypofunction in cirrhosis is not associated with increased risk for infections

295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy

831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3

Suchergebnisse filtern